Akero Therapeutics (AKRO) reported 96-week data in its trial of advanced MASH patients, and there seem really significant ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

The results of a phase 2b ENLIVEN trial of FGF21 analogue pegozafermin showed it was able to reduce scarring (fibrosis) in the liver of NASH patients at more than three times the rate of a placebo ...

Akero Therapeutics nearly doubled Monday — and pulled 89bio shares higher — after the company's treatment for MASH ...

Along with NASH, Novo Nordisk is also planning to investigate ... phase 3 in combination with drugs from Gilead, a long-acting FGF21 analogue in phase 2, and early-stage candidates partnered ...

Tyson Nash was known as a “pest” during his six years in the NHL playing for the St. Louis Blues and Phoenix Coyotes, and it’s a title he embraced. Nash, now broadcasting for the Utah Hockey ...

(ETNB) stock jumped 40% Monday, stoked by positive data for Akero's (AKRO) drug efruxifermin in the treatment of compensated ...

Nash & Smashed in the Woodmoor Shopping Center in Silver Spring. The signage, which went up in August 2024, reflects the name of the restaurant before it's rebrand to it's current name. Photo ...

Nash Equilibrium is a fundamental concept in game theory that describes a situation where no player can benefit by changing their strategy while the other players keep theirs unchanged. This ...

pegozafermin (BIO89-100) is under development for the treatment of non-alcoholic steatohepatitis (NASH), liver cirrhosis, fibrosis and severe hypertriglyceridemia. It is a long-acting glycopegylated ...